To the full analysis
Sanofi stock: growth
SAN.PASanofi reported $51.77B in revenue for fiscal 2025, up 5.5% on the prior year, up 4.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
2.5%
per year from 2006 to 2025, per share 3%
Earnings (Annual rate)
3.6%
per year from 2006 to 2025, per share 4.1%
Free cash flow (Annual rate)
3%
per year from 2006 to 2025, per share 3.5%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 4.6% | 3.0% | 2.5% |
| Revenue per share | 5.1% | 3.7% | 3.0% |
| Earnings | −8.7% | 6.2% | 3.6% |
| Earnings per share | −8.2% | 6.9% | 4.1% |
| Free cash flow | 11.0% | 3.9% | 3.0% |
| Free cash flow per share | 11.6% | 4.6% | 3.5% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $32.68B | $4.44B | $5.71B |
| 2007 | $32.42B | $5.84B | $6.1B |
| 2008 | $31.93B | $7.96B | $7.66B |
| 2009 | $34.07B | $5.83B | $7.46B |
| 2010 | $35.5B | $4.83B | $9.07B |
| 2011 | $38.85B | $6.31B | $8.35B |
| 2012 | $39.84B | $5.42B | $7.27B |
| 2013 | $34.67B | $4.12B | $6.16B |
| 2014 | $35.46B | $4.86B | $6.8B |
| 2015 | $38.63B | $4.75B | $6.81B |
| 2016 | $38.45B | $5.22B | $6.38B |
| 2017 | $40.14B | $9.33B | $6.01B |
| 2018 | $39.53B | $4.77B | $3.96B |
| 2019 | $41.7B | $3.05B | $6.57B |
| 2020 | $41.41B | $13.62B | $5.91B |
| 2021 | $43.41B | $6.9B | $9.4B |
| 2022 | $44.66B | $9.28B | $9.22B |
| 2023 | $45.55B | $5.98B | $9.57B |
| 2024 | $49.07B | $6.16B | $6.52B |
| 2025 | $51.77B | $8.66B | $9.96B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Apr 2024)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.